1. Kobayashi H, Kokubo T, Takahashi M, Sato K, Miyokawa N, Kimura S, Kinouchi R, Katagiri M (1998) Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient. Immunogenetics 47: 398-403 DOI 10.1007/s002510050375
2. O'Keefe GA, Rao NA (2017) Vogt-Koyanagi-Harada disease. Surv Ophthalmol 62: 1-25 DOI 10.1016/j.survophthal.2016.05.002
3. Norose K, Yano A (1996) Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease. Br J Ophthalmol 80: 1002-1008 DOI 10.1136/bjo.80.11.1002
4. Baltmr A, Lightman S, Tomkins-Netzer O (2016) Vogt-Koyanagi-Harada syndrome - current perspectives. Clin Ophthalmol 10: 2345-2361 DOI 10.2147/OPTH.S94866
5. Rubsamen PE, Gass JDM (1991) Vogt-Koyanagi-Harada Syndrome: Clinical Course, Therapy, and Long-term Visual Outcome. Archives of Ophthalmology 109: 682-687 DOI 10.1001/archopht.1991.01080050096037
6. Chee SP, Jap A, Bacsal K (2009) Prognostic factors of Vogt-Koyanagi-Harada disease in Singapore. Am J Ophthalmol 147: 154-161 e151 DOI 10.1016/j.ajo.2008.07.044
7. Kitaichi N, Horie Y, Ohno S (2008) Prompt therapy reduces the duration of systemic corticosteroids in Vogt-Koyanagi-Harada disease. Graefes Arch Clin Exp Ophthalmol 246: 1641-1642 DOI 10.1007/s00417-008-0869-5
8. Sasamoto Y, Ohno S, Matsuda H (1990) Studies on Corticosteroid Therapy in Vogt-Koyanagi-Harada Disease. Ophthalmologica 201: 162-167 DOI 10.1159/000310145
9. Lai TY, Chan RP, Chan CK, Lam DS (2009) Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Eye (Lond) 23: 543-548 DOI 10.1038/eye.2008.89
10. Read RW, Rechodouni A, Butani N, Johnston R, LaBree LD, Smith RE, Rao NA (2001) Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol 131: 599-606 DOI 10.1016/s0002-9394(01)00937-0
11. Nakayama M, Keino H, Watanabe T, Okada AA (2019) Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids. Br J Ophthalmol 103: 274-278 DOI 10.1136/bjophthalmol-2017-311691
12. Sakata VM, da Silva FT, Hirata CE, Marin ML, Rodrigues H, Kalil J, Costa RA, Yamamoto JH (2015) High rate of clinical recurrence in patients with Vogt-Koyanagi-Harada disease treated with early high-dose corticosteroids. Graefes Arch Clin Exp Ophthalmol 253: 785-790 DOI 10.1007/s00417-014-2904-z
13. RUSSELL W. READ M, GARY N. HOLLAND, MD, NARSING A. RAO, MD,, KHALID F. TABBARA M, SHIGEAKI OHNO, MD, LOURDES ARELLANES-GARCIA, MD, PAOLA PIVETTI-PEZZI, MD, HOWARD H. TESSLER, MD, AND MASAHIKO USUI, MD (2001) Revised Diagnostic Criteria for
Vogt-Koyanagi-Harada Disease: Report of an International Committee on Nomenclature. Am J Ophthalmol
14. Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, Ozono K, Sagawa A, Takayanagi R, Tanaka H, Miki T, Masunari N, Tanaka Y (2014) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab 32: 337-350 DOI 10.1007/s00774-014-0586-6
15. Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140: 509-516 DOI 10.1016/j.ajo.2005.03.057
16. Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48: 452-458 DOI 10.1038/bmt.2012.244
17. Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, Pivetti-Pezzi P, Tessler HH, Usui M (2001) Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 131: 647-652 DOI 10.1016/s0002-9394(01)00925-4
18. Shen E, Rathinam SR, Babu M, Kanakath A, Thundikandy R, Lee SM, Browne EN, Porco TC, Acharya NR (2016) Outcomes of Vogt-Koyanagi-Harada Disease: A Subanalysis From a Randomized Clinical Trial of Antimetabolite Therapies. Am J Ophthalmol 168: 279-286 DOI 10.1016/j.ajo.2016.06.004
19. Yang P, Liu S, Zhong Z, Du L, Ye Z, Zhou W, Kijlstra A (2019) Comparison of Clinical Features and Visual Outcome between Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Disease in Chinese Patients. Ophthalmology 126: 1297-1305 DOI 10.1016/j.ophtha.2019.03.049
20. Giordano VE, Schlaen A, Guzman-Sanchez MJ, Couto C (2017) Spectrum and visual outcomes of Vogt-Koyanagi-Harada disease in Argentina. Int J Ophthalmol 10: 98-102 DOI 10.18240/ijo.2017.01.16
21. Arevalo JF, Lasave AF, Gupta V, Kozak I, Al Harbi MB, Al Rushood AA, Al Dhibi HA (2016) Clinical Outcomes of Patients with Vogt-Koyanagi-Harada Disease Over 12 Years at a Tertiary Center. Ocul Immunol Inflamm 24: 521-529 DOI 10.3109/09273948.2015.1025984
22. Iwahashi C, Okuno K, Hashida N, Nakai K, Ohguro N, Nishida K (2015) Incidence and clinical features of recurrent Vogt-Koyanagi-Harada disease in Japanese individuals. Jpn J Ophthalmol 59: 157-163 DOI 10.1007/s10384-015-0377-1
23. Rao NA, Sukavatcharin S, Tsai JH (2007) Vogt-Koyanagi-Harada disease diagnostic criteria. Int Ophthalmol 27: 195-199 DOI 10.1007/s10792-006-9021-x
24. Kitamura M, Takami K, Kitaichi N, Namba K, Kitamei H, Kotake S, Ohno S (2005) Comparative study of two sets of criteria for the diagnosis of Vogt-Koyanagi-Harada's disease. Am J Ophthalmol 139: 1080-1085 DOI 10.1016/j.ajo.2005.01.046
25. Ikeda N, Kojima H, Nishikawa M, Hayashi K, Futagami T, Tsujino T, Kusunoki Y, Fujii N, Suegami S, Miyazaki Y, Middleton D, Tanaka H, Saji H (2015) Determination of HLA-A, -C, -B, -DRB1 allele and haplotype frequency in Japanese population based on family study. Tissue Antigens 85: 252-259 DOI 10.1111/tan.12536
26. Shindo Y, Ohno S, Yamamoto T, Nakamura S, Inoko H (1994) Complete association of the HLA-DRB1 ∗04 and -DQB1 ∗04 alleles with Vogt-Koyanagi-Harada's disease. Human Immunology 39: 169-176 DOI https://doi.org/10.1016/0198-8859(94)90257-7
27. Read RW, Yu F, Accorinti M, Bodaghi B, Chee SP, Fardeau C, Goto H, Holland GN, Kawashima H, Kojima E, Lehoang P, Lemaitre C, Okada AA, Pivetti-Pezzi P, Secchi A, See RF, Tabbara KF, Usui M, Rao NA (2006) Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Am J Ophthalmol 142: 119-124 DOI 10.1016/j.ajo.2006.02.049
28. Park UC, Cho IH, Lee EK, Yu HG (2017) The effect on choroidal changes of the route of systemic corticosteroids in acute Vogt-Koyanagi-Harada disease. Graefes Arch Clin Exp Ophthalmol 255: 1203-1211 DOI 10.1007/s00417-017-3654-5
29. Herbort CP, Jr., Abu El Asrar AM, Yamamoto JH, Pavésio CE, Gupta V, Khairallah M, Tugal-Tutkun I, Soheilian M, Takeuchi M, Papadia M (2017) Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality. Int Ophthalmol 37: 1383-1395 DOI 10.1007/s10792-016-0395-0
30. White KP, Driscoll MS, Rothe MJ, Grant-Kels JM (1994) Severe adverse cardiovascular effects of pulse steroid therapy: is continuous cardiac monitoring necessary? J Am Acad Dermatol 30: 768-773 DOI 10.1016/s0190-9622(08)81508-3